L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lytix Biopharma AS
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Additional Paid In Capital
kr47.3m
CAGR 3-Years
40%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bergenbio ASA
OSE:BGBIO
Additional Paid In Capital
kr8.8m
CAGR 3-Years
-72%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Additional Paid In Capital
kr265.8m
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
8%
N
Nykode Therapeutics ASA
OSE:NYKD
Additional Paid In Capital
$129m
CAGR 3-Years
28%
CAGR 5-Years
17%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Additional Paid In Capital
kr61.5m
CAGR 3-Years
-51%
CAGR 5-Years
-40%
CAGR 10-Years
-6%
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

What is Lytix Biopharma AS's Additional Paid In Capital?
Additional Paid In Capital
47.3m NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Additional Paid In Capital amounts to 47.3m NOK.

What is Lytix Biopharma AS's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
6%

Over the last year, the Additional Paid In Capital growth was -64%. The average annual Additional Paid In Capital growth rates for Lytix Biopharma AS have been 40% over the past three years , 6% over the past five years .

Back to Top